GLP-1 medications are titrated — you start at a low dose and increase gradually over weeks or months until you reach a therapeutic level. This process exists for a reason: it gives your body time to adjust, reduces the severity of side effects, and helps your clinician identify the optimal dose for your individual response.
But not all providers handle titration the same way. Some follow conservative schedules with built-in flexibility. Others rush patients to higher doses on aggressive timelines that prioritize speed over comfort. The difference can determine whether your first few months on GLP-1s are manageable or miserable.
The Standard Titration Framework
For semaglutide, the FDA-approved titration schedule for Wegovy looks like this: start at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then the maintenance dose of 2.4 mg. That's a minimum of 16 weeks — four months — to reach the target dose.
This schedule was established through clinical trials where it was shown to balance efficacy with tolerability. It's not arbitrary. The reason each dose level lasts 4 weeks is that GLP-1 receptor adaptation takes time, and the most common side effects (nausea, GI distress) peak in the days after each dose increase and diminish as your body acclimates.
How Providers Deviate
The slow and flexible approach
Some providers extend the standard timeline, keeping patients at each dose level for 6–8 weeks instead of 4. Dose increases happen only after a clinical check-in confirms that the patient is tolerating the current level well. If side effects are significant, the provider holds the dose or even temporarily reduces it.
This approach is slower but tends to produce fewer side-effect-driven dropouts. Patients who might have quit at week 3 due to severe nausea on an aggressive timeline stay in treatment because their side effects remain manageable.
The standard approach
Following the FDA schedule — 4 weeks per dose level — with adjustments based on individual response. This is what most reputable providers do. It's well-supported by clinical evidence and balances speed with tolerability for most patients.
The accelerated approach
Some providers compress the titration timeline, moving patients up every 2–3 weeks instead of 4. The clinical justification is typically "getting patients to a therapeutic dose faster" — but the real driver is often economic. Faster titration means patients reach higher (more expensive) doses sooner, and providers who bill by dose level generate more revenue per patient per month.
The one-size-fits-all approach
The most concerning pattern we found: providers with fixed titration schedules that apply to every patient regardless of individual response. Month 1 is 0.25 mg. Month 2 is 0.5 mg. Month 3 is 1.0 mg. No flexibility, no clinical judgment, no accommodation for patients who need more time.
This isn't medicine. It's a fulfillment calendar.
What Matters for Your Experience
The titration timeline directly affects two things patients care about most:
Side effect severity. Faster titration means more intense side effects at each step. Some patients handle this fine. Others experience nausea severe enough to affect their daily lives, their work, and their ability to eat. If your provider's protocol doesn't account for individual variation, you'll either suffer through it or drop out.
Long-term adherence. Research consistently shows that patients who have a manageable early experience are more likely to stay on treatment long-term. Aggressive titration that produces severe early side effects creates dropouts — patients who might have succeeded with a gentler approach but quit before reaching a therapeutic dose.
Questions to Ask About Your Titration
- What is your standard titration schedule? How closely does it follow FDA labeling?
- Can the schedule be adjusted if I experience significant side effects?
- Is there a clinical assessment before each dose increase?
- What happens if I want to stay at a lower dose longer than the standard timeline?
- Who decides when my dose increases — the protocol or my clinician?
These providers offer flexible, clinician-directed dose escalation:
Providers Worth Investigating
We evaluated these programs based on the criteria discussed in this article. Listings are paid partnerships — our analysis is independent.